This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Pinewood Healthcare

Ballymacarby, Clonmel, Co. Tipperary, Co. Tipperary, Ireland
Telephone: +353 52 6186000
Fax: + 353 52 6136311
WWW: http://www.pinewood.ie
Medical Information Direct Line: +44 1978 661 261
Medical Information e-mail: drug.safety@wockhardt.co.uk
Medical Information Fax: +44 1978 661 702

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 10/03/2014
SPC Loratadine 5 mg/5 ml Syrup


Go to top of the page
1. Name of the medicinal product

Loratadine 5 mg/5 ml Syrup

Boots Hayfever Relief All Day 5mg/5ml Oral Solution


Go to top of the page
2. Qualitative and quantitative composition

Each 1ml of syrup contains 1mg loratadine.

Each 1 ml of syrup also contains the following excipients:

0.11 g glycerol (E422)

0.11 g propylene glycol

0.6 g sucrose

For a full list of excipients, see section 6.1.


Go to top of the page
3. Pharmaceutical form

Oral Solution

Colour free, Peach flavour


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Loratadine 5mg/5ml Syrup is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.


Go to top of the page
4.2 Posology and method of administration

For oral administration

Adults and children over 12 years of age: 10ml (10mg) of the syrup once daily.

Children 2 to 12 years of age with:

Body weight more than 30kg: 10ml (10mg) of the syrup once daily;

Body weight 30kg or less: 5ml (5mg) of the syrup once daily.

Efficacy and safety of Loratadine 5mg/5ml Syrup in children under 2 years of age has not been established.

Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine. An initial dose of 10mg every other day is recommended for adults and children weighing more than 30kg, and for children weighing 30kg or less, 5ml (5mg) every other day is recommended.

No dosage adjustments are required in the elderly or in patients with renal insufficiency.


Go to top of the page
4.3 Contraindications

Loratadine 5mg/5ml Syrup is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients in this formulation.


Go to top of the page
4.4 Special warnings and precautions for use

Loratadine 5mg/5ml Syrup should be administered with caution in patients with severe liver impairment (see section 4.2).

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

The administration of Loratadine 5mg/5ml Syrup should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

When administered concomitantly with alcohol, Loratadine 5mg/5ml Syrup has no potentiating effects as measured by psychomotor performance studies.

Due to the wide therapeutic index of loratadine no clinically relevant interactions are expected and none were observed in the conducted clinical trials (see section 5.2).


Go to top of the page
4.6 Pregnancy and lactation

Loratadine was not teratogenic in animal studies. The safe use of loratadine during pregnancy has not been established. The use of Loratadine 5mg/5ml Syrup during pregnancy is therefore not recommended.

Loratadine is excreted in breast milk, therefore the use of loratadine is not recommended in breast-feeding women.


Go to top of the page
4.7 Effects on ability to drive and use machines

In clinical trials that assessed driving ability, no impairment occurred in patients receiving loratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.


Go to top of the page
4.8 Undesirable effects

In clinical trials in a paediatric population children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue (1%).

In clinical trials involving adults and adolescents in a range of indications including AR and CIU, at the recommended dose of 10mg daily, adverse reactions with loratadine were reported in 2% of patients in excess of those treated with the placebo. The most frequent adverse reactions reported in excess of placebo were somnolence (1.2%), headache (0.6%), increased appetite (0.5%) and insomnia (0.1%). Other adverse reactions reported very rarely during the post-marketing period are listed in the following table:

Immune disorders

Anaphylaxis

Nervous system disorders

Dizziness

Cardiac disorders

Tachycardia, palpitation

Gastrointestinal disorders

Nausea, dry mouth, gastritis

Hepato-biliary disorders

Abnormal hepatic function

Skin and subcutaneous tissue disorders

Rash, alopecia

General disorders and administration site conditions

Fatigue


Go to top of the page
4.9 Overdose

Overdosage with loratadine increased the occurrence of anticholinergic symptoms. Somnolence, tachycardia, and headache have been reported with overdoses.

In the event of overdose, general symptomatic and supportive measures are to be instituted and maintained for as long as necessary. Administration of activated charcoal as a slurry with water may be attempted. Gastric lavage may be considered. Loratadine is not removed by haemodialysis and it is not known if loratadine is removed by peritoneal dialysis. Medical monitoring of the patient is to be continued after emergency treatment.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: anti histamines – H1 antagonist, ATC code: R06A X13.

Loratadine, the active ingredient in Loratadine 5mg/5ml Syrup, is a tricyclic antihistamine with selective, peripheral H1-receptor activity.

Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage. During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms.

Loratadine has no significant H2-receptor activity. It does not inhibit norepinephrine uptake and has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.


Go to top of the page
5.2 Pharmacokinetic properties

After oral administration, loratadine is rapidly and well absorbed and undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite-desloratadine (DL)- is pharmacologically active and responsible for a large part of the clinical effect. Loratadine and DL achieve maximum plasma concentrations (Tmax) between 1-1.5 hours and 1.5-3.7 hours after administration, respectively.

Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Loratadine is highly bound (97% to 99%) and its active metabolite moderately bound (73% to 76%) to plasma proteins.

In healthy subjects, plasma distribution half-lives of loratadine and its active metabolite are approximately 1 and 2 hours, respectively. The mean elimination half lives in healthy adult subjects were 8.4 hours (range=3 to 20 hours) for loratadine and 28 hours (range-8.8 to 92 hours for the major active metabolite).

Approximately 40% of the dose is excreted in the urine and 42% in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27% of the dose is eliminated in the urine during the first 24 hours. Less than 1% of the active substance is excreted unchanged in active form, as loratadine or DL.

The bioavailability parameters of loratadine and of the active metabolite are dose proportional.

The pharmacokinetic profile of loratadine and its metabolites is comparable in healthy adult volunteers and in healthy geriatric volunteers.

Concomitant ingestion of food can delay slightly the absorption of loratadine but without influencing the clinical effect.

In patients with chronic renal impairment, both the AUC and peak plasma levels (Cmax) increased for loratadine and its metabolite as compared to the AUCs and peak plasma levels (Cmax) of patients with normal renal function. The mean elimination half-lives of loratadine and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of loratadine or its active metabolite in subjects with chronic renal impairment.

In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (Cmax) of loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.

Loratadine and its active metabolite are excreted in the breast milk of lactating women.


Go to top of the page
5.3 Preclinical safety data

Preclinical data reveal no special hazard based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.

In reproductive toxicity studies, no teratogenic effects were observed. However, prolonged parturition and reduced viability of offspring were observed in rats at plasma levels (AUC) 10 times higher than those achieved with clinical doses.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Propylene glycol

Glycerol (E422)

Sodium Benzoate (E211)

Citric Acid Monohydrate

Sucrose

Purified Water

Peach Flavour


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

Shelf life before opening - 2 years

Shelf life after opening - 6 months


Go to top of the page
6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.


Go to top of the page
6.5 Nature and contents of container

Bottle made from Type III Amber Glass with a tamper evident child resistant closure having a polypropylene outer layer and a polyethylene inner layer. This product is provided with a measuring device.

Pack Sizes: 60 ml, 100 ml and 150 ml.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. Marketing authorisation holder

Pinewood Laboratories Limited trading as Pinewood Healthcare

Ballymacarbry

Clonmel

Co. Tipperary

Ireland


Go to top of the page
8. Marketing authorisation number(s)

PL 04917/0067


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

11/07/2011


Go to top of the page
10. Date of revision of the text

01/2014



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/24482/SPC/


Active Ingredients/Generics